Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Gabapentin for Symptomatic Scarring Alopecia
NCT03346668Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Jan 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gabapentin in Scarring alopecia (CA), sponsored by University of Minnesota. Primary endpoints: Neurogenic inflammation-Quality of Life at 14 weeks, Short Form (36) Health Survey at 14 weeks and 1 more. Started Jan 2016; status: completed.
02
Drugs
gabapentin
03
Conditions
Scarring alopecia (CA)
Beyond the preview
Go deeper on NCT03346668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346668.